Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tenaya Therapeutics Inc

0.4515
-0.0033-0.73%
Post-market: 0.45610.0046+1.02%19:46 EDT
Volume:1.46M
Turnover:675.79K
Market Cap:72.94M
PE:-0.34
High:0.4860
Open:0.4700
Low:0.4500
Close:0.4548
Loading ...

Tenaya Therapeutics’ Senior VP Resigns for New Opportunity

TIPRANKS
·
17 Dec 2024

Tenaya Therapeutics Inc - Chihro Saito Resigns as Svp, Afo and Interim Pao of Tenaya

THOMSON REUTERS
·
17 Dec 2024

Tenaya reported early data from first cohort of patients in MyPEAK-1 trial

TIPRANKS
·
17 Dec 2024

Tenaya Therapeutics Reports Promising Early Data From Mypeak™-1 Phase 1B/2 Clinical Trial of Tn-201 for Treatment of Mybpc3-Associated Hypertrophic Cardiomyopathy

THOMSON REUTERS
·
17 Dec 2024

Tenaya Therapeutics Inc - Tn-201 Well Tolerated With Increasing Rna and Protein Levels

THOMSON REUTERS
·
17 Dec 2024

Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

GlobeNewswire
·
17 Dec 2024

Tenaya Therapeutics to announce initial data from Phase 1b/2 trial of TN-201

TIPRANKS
·
17 Dec 2024

BRIEF-Tenaya Therapeutics To Announce Initial Data From Mypeak-1 Phase 1B/2 Clinical Trial Of TN-201 Gene Therapy For Mybpc3-Associated Hypertrophic Cardiomyopathy On Tuesday, December 17, 2024

Reuters
·
17 Dec 2024

Tenaya Therapeutics to Announce Initial Data From Mypeak-1 Phase 1B/2 Clinical Trial of Tn-201 Gene Therapy for Mybpc3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

THOMSON REUTERS
·
17 Dec 2024

Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

GlobeNewswire
·
17 Dec 2024

Tenaya Therapeutics Price Target Announced at $18.00/Share by HC Wainwright & Co.

Dow Jones
·
26 Nov 2024

Positive Outlook for Tenaya Therapeutics Amidst Strategic Advancements in PKP2-ARVC Gene Therapy

TIPRANKS
·
26 Nov 2024

Positive Outlook for Tenaya Therapeutics: Strong Potential in Gene Therapy for Cardiovascular Diseases Supports Buy Rating

TIPRANKS
·
26 Nov 2024

BRIEF-Tenaya Therapeutics Doses First Patient In Ridge-1 Phase 1B Clinical Trial Of TN-401

Reuters
·
25 Nov 2024

Tenaya Therapeutics Doses First Patient in Ridge™-1 Phase 1B Clinical Trial of Tn-401 for the Treatment of Pkp2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

THOMSON REUTERS
·
25 Nov 2024

Tenaya Therapeutics Inc - Initial Clinical Data for Ridge-1 Expected in 2025

THOMSON REUTERS
·
25 Nov 2024

Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

GlobeNewswire
·
25 Nov 2024

Tenaya Therapeutics reports inducement grants under Nasdaq listing rule

TIPRANKS
·
19 Nov 2024

BRIEF-Tenaya Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
19 Nov 2024

Tenaya Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
19 Nov 2024